Characteristics and Outcomes of Adult Patients in the PETHEMA Registry with Relapsed or Refractory FLT3-ITD Mutation-Positive Acute Myeloid Leukemia.
- Martínez-Cuadrón, David
- Serrano, Josefina
- Mariz, José
- Gil, Cristina
- Tormo, Mar
- Martínez-Sánchez, Pilar
- Rodríguez-Arbolí, Eduardo
- García-Boyero, Raimundo
- Rodríguez-Medina, Carlos
- Martínez-Chamorro, Carmen
- Polo, Marta
- Bergua, Juan
- Aguiar, Eliana
- Amigo, María L
- Herrera, Pilar
- Alonso-Domínguez, Juan M
- Bernal, Teresa
- Espadana, Ana
- Sayas, María J
- Algarra, Lorenzo
- Vidriales, María B
- Vasconcelos, Graça
- Vives, Susana
- Pérez-Encinas, Manuel M
- López, Aurelio
- Noriega, Víctor
- García-Fortes, María
- Chillón, María C
- Rodríguez-Gutiérrez, Juan I
- Calasanz, María J
- Labrador, Jorge
- López, Juan A
- Boluda, Blanca
- Rodríguez-Veiga, Rebeca
- Martínez-López, Joaquín
- Barragán, Eva
- Sanz, Miguel A
- Montesinos, Pau
- On Behalf Of The Pethema Group,
DOIAbstract
This retrospective study investigated outcomes of 404 patients with relapsed/refractory (R/R) FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD) acute myeloid leukemia (AML) enrolled in the PETHEMA registry, pre-approval of tyrosine kinase inhibitors. Most patients (63%) had received first-line intensive therapy with 3 + 7. Subsequently, patients received salvage with intensive therapy (n = 261), non-intensive therapy (n = 63) or supportive care only (n = 80). Active salvage therapy (i.e., intensive or non-intensive therapy) resulted in a complete remission (CR) or CR without hematological recovery (CRi) rate of 42%. More patients achieved a CR/CRi with intensive (48%) compared with non-intensive (19%) salvage therapy (
Add to ORKG